Ocular Therapeutix (OCUL) Gross Profit (2014 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Gross Profit of $11.5 million for Q2 2026, little changed year-over-year from $11.5 million in Q2 2025, and up 21.24% on a QoQ basis from $9.5 million in Q1 2026.
Ocular Therapeutix (OCUL) Gross Profit (2014 - 2026) Analysis & Trends
Ocular Therapeutix has reported Gross Profit for 13 years, with the latest figure at $11.5 million in Q2 2026.
- Gross Profit for Q2 2026 came in at $11.5 million, changed 0.44% year-over-year; the trailing twelve-month figure through Jun 2026 was $45.3 million (down 10.5% YoY), and the FY2025 annual result was $45.4 million, down 21.89% from the prior year.
- Gross Profit climbed to $11.5 million in Q2 2026, from $9.5 million in the prior quarter.
- Over five years, Gross Profit peaked at $15.9 million in Q4 2024 and troughed at $9.4 million in Q1 2025.
- A 5-year average of $12.5 million and a median of $12.5 million in 2023 frame the typical range for Gross Profit.
- The widest annual swing landed in 2022, when Gross Profit soared 84.29%; it then slipped 29.83% in 2025.
- A 5-year view of Gross Profit shows it stood at $13.1 million in 2022, then climbed by 2.69% to $13.4 million in 2023, then rose by 18.17% to $15.9 million in 2024, then declined by 26.47% to $11.7 million in 2025, then slipped by 1.65% to $11.5 million in 2026.
- Per Business Quant data, the three most recent Gross Profit figures were $11.5 million in Q2 2026, $9.5 million in Q1 2026, and $11.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.46 Mn |
| Jun 30, 2026 | 11.46 Mn |
| Mar 31, 2026 | 9.46 Mn |
| Mar 31, 2026 | 9.46 Mn |
| Dec 31, 2025 | 11.66 Mn |
| Dec 31, 2025 | 11.66 Mn |
| Sep 30, 2025 | 12.77 Mn |
| Sep 30, 2025 | 12.77 Mn |
| Jun 30, 2025 | 11.52 Mn |
| Jun 30, 2025 | 11.52 Mn |
| Mar 31, 2025 | 9.44 Mn |
| Mar 31, 2025 | 9.44 Mn |
| Dec 31, 2024 | 15.85 Mn |
| Dec 31, 2024 | 15.85 Mn |
| Sep 30, 2024 | 13.86 Mn |
| Sep 30, 2024 | 13.86 Mn |
| Jun 30, 2024 | 14.93 Mn |
| Jun 30, 2024 | 14.93 Mn |
| Mar 31, 2024 | 13.45 Mn |
| Mar 31, 2024 | 13.45 Mn |